Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease

Molecular Vision

Volumn 19, Issue , 2013, Pages 1957-1965

  Vijmasi, Trinka ^a   Chen, Feeling Y T ^a   Chen, Ying Ting ^a   Gallup, Marianne ^a   McNamara, Nancy ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMETHYLCELLULOSE; DYE; GLYCOPROTEIN P 15095; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR TYPE I; LECTIN; LEUKOAGGLUTININ; MEMBRANE PROTEIN; MUCIN; PHENOLSULFONPHTHALEIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; REFRESH LIQUIGEL; SMALL PROLINE RICH PROTEIN 1B; T LYMPHOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE REGULATOR GENE; CD4+ T LYMPHOCYTE; CELL COUNT; CELL INFILTRATION; CLINICAL FEATURE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRY EYE; EYE INJURY; GENE; GENE EXPRESSION; GOBLET CELL; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; KERATINIZATION; KERATOCONJUNCTIVITIS SICCA; LACRIMATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; ANIMALS; AQUEOUS HUMOR; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; DRY EYE SYNDROMES; GENE EXPRESSION REGULATION; GLYCOSYLATION; GOBLET CELLS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; KERATINS; LEUKOCYTES; MICE; MICE, KNOCKOUT; MUCINS; TEARS;

EID: 84884381491     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Research in dry eye: report of the Research Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:179-93. [PMID: 17508121].
2. Chen YT, Nikulina K, Lazarev S, Bahrami AF, Noble LB, Gallup M, McNamara NA. Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjogren's syndrome. Am J Pathol 2010; 177:1333-43. [PMID: 20696775].
3. Chen YT, Li S, Nikulina K, Porco T, Gallup M, McNamara N. Immune profile of squamous metaplasia development in autoimmune regulator-deficient dry eye. Mol Vis 2009; 15:563-76.
4. Chen YT, Lazarev S, Bahrami AF, Noble LB, Chen FY, Zhou D, Gallup M, Yadav M, McNamara NA. Interleukin-1 receptor mediates the interplay between CD4(+) T cells and ocular resident cells to promote keratinizing squamous metaplasia in Sjogren's syndrome. Lab Invest 2012; 92.4:556-570. [PMID: 22231738].
5. Li S, Gallup M, Chen YT, McNamara N. Molecular Mechanism of Proinflammatory Cytokine-Mediated Squamous Metaplasia in Human Corneal Epithelial Cells. Invest Ophthalmol Vis Sci 2010; 51.5:2466-2475. [PMID: 20042643].
6. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro-and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 2001; 42:2283-92. [PMID: 11527941].
7. Stapleton WM, Chaurasia SS, Medeiros FW, Mohan RR, Sinha S, Wilson SE. Topical interleukin-1 receptor antagonist inhibits inflammatory cell infiltration into the cornea. Exp Eye Res 2008; 86:753-7. [PMID: 18346730].
8. Okanobo A, Chauhan SK, Dastjerdi MH, Kodati S, Dana R. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol 2012; 154:63-71. [PMID: 22541929].
9. Li S, Nikulina K, DeVoss J, Wu AJ, Strauss EC, Anderson MS, McNamara NA. Small proline-rich protein 1B (SPRR1B) is a biomarker for squamous metaplasia in dry eye disease. Invest Ophthalmol Vis Sci 2008; 49:34-41. [PMID: 18172072].
10. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004; 137:337-42. [PMID: 14962426].
11. McCabe E, Narayanan S. Advancements in anti-inflammatory therapy for dry eye syndrome. Optometry 2009; 80:555-66. [PMID: 19801339].
12. Amparo F, Dastjerdi MH, Okanobo A, Ferrari G, Smaga L, Hamrah P, Jurkunas U, Schaumberg DA, Dana R. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol 2013; 131:715-23.
13. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:75-92. [PMID: 17508116].
14. Dartt DA. Neural regulation of lacrimal gland secretory processes: relevance in dry eye diseases. Prog Retin Eye Res 2009; 28:155-77. [PMID: 19376264].
15. Gipson IK, Hori Y, Argueso P. Character of ocular surface mucins and their alteration in dry eye disease. Ocul Surf 2004; 2:131-48. [PMID: 17216084].
16. An HJ, Ninonuevo M, Aguilan J, Liu H, Lebrilla CB, Alvarenga LS, Mannis MJ. Glycomics analyses of tear fluid for the diagnostic detection of ocular rosacea. J Proteome Res 2005; 4:1981-7. [PMID: 16335942].
17. Varki A, Gagneux P. Multifarious roles of sialic acids in immunity. Ann N Y Acad Sci 2012; 1253:16-36. [PMID: 22524423].
18. Schauer R. Sialic acids as regulators of molecular and cellular interactions. Curr Opin Struct Biol 2009; 19:507-14. [PMID: 19699080].
19. Marth JD, Grewal PK. Mammalian glycosylation in immunity. Nat Rev Immunol 2008; 8:874-87. [PMID: 18846099].
20. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007; 7:255-66. [PMID: 17380156].
21. Crocker PR, Varki A. Siglecs, sialic acids and innate immunity. Trends Immunol 2001; 22:337-42. [PMID: 11377294].
22. Pillai S, Netravali IA, Cariappa A, Mattoo H. Siglecs and immune regulation. Annu Rev Immunol 2012; 30:357-92. [PMID: 22224769].
23. Zhou D, Chen YT, Chen F, Gallup M, Vijmasi T, Bahrami AF, Noble LB, van Rooijen N, McNamara NA. Critical involvement of macrophage infiltration in the development of Sjogren's syndrome-associated dry eye. Am J Pathol 2012; 181:753-60. [PMID: 22770665].